Ann: Mesoblast Webcast, page-115

The first one did ask but because he either sidestepped the question or he didn't know the answer because the data is blinded. He talked about how the first half was mostly patients under 50 and it was effective and the second half was less effective where the patients were over 60 and 70 and were treated for longer before ventilating so the results were very different for the 2 halves. That led into the discussion about how the sweet spot is when there is inflammation but early enough for cells to respond and the have effect but not so advanced to be irretrievable. So for the treatment to be effective, they need to be 1st or 2nd in line in treatments, not last resort. At least that is my recollection.